Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
ArrePath is a company focused on discovering anti-infective drugs to tackle the global issue of drug-resistant infections. It operates a drug discovery platform that aims to develop therapies specifically targeting antimicrobial resistance. The platform is designed to create new medicines that address multiple targets within disease pathways, which may enhance treatment efficacy while minimizing risks during the discovery and development phases. This approach supports healthcare professionals in treating chronic infections and improving patient recovery times.
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.
Amberstone Biosciences specializes in the discovery of novel immunotherapies aimed at addressing unmet medical needs through advanced technologies and strategic collaborations. The company focuses on challenging therapeutic targets that require unique mechanisms of action, which traditional methods struggle to tackle. Amberstone employs a microfluidics-powered drug discovery platform, known as AmberFlow, to analyze single-cell functions within a customizable microenvironment. This innovative approach allows for a more precise understanding of immune responses, enabling the development of transformative therapeutic antibodies. The team's expertise in immuno-oncology and single-cell assay biology further enhances their capacity to create effective treatments, ultimately improving patient outcomes.
Fuse Biotherapeutics is a biotechnology company focused on developing innovative immune-modulating therapeutics for cancer patients. Established in 2021 and based in Los Angeles, the company employs a rational approach to its therapeutic development, integrating multiple steps of the immune response. This approach aims to harness potent immune responses to target cancer effectively while preserving the natural mechanisms that protect healthy tissues. By prioritizing safety alongside efficacy, Fuse Biotherapeutics seeks to create new treatment options that offer advantages over existing therapies in the cancer treatment landscape.
Deka Biosciences
Series A in 2021
Early stage biotechnology start-up developing next generation cytokine therapeutics
IpiNovyx Bio is a biopharmaceutical company developing a platform of best-in-class immunoproteasome modulating therapeutics to transform the treatment of autoimmune and inflammatory diseases.
Karma Biotechnologies, Inc. develops therapies for autoimmune diseases. It offers Xavines, a therapeutic to treat autoimmunity, allergies, and food sensitivities. Karma Biotechnologies, Inc. was incorporated in 2019 and is based in Los Angeles, California.
Grove Biopharma is a biotechnology company dedicated to addressing unmet medical needs in oncology, chronic inflammatory, and neurodegenerative diseases. It specializes in the discovery and development of a new class of protein-like polymers, utilizing artificial intelligence and precision polymer chemistry to create hybrid synthetic protein mimetics. The company also provides materials science solutions to tackle challenges associated with peptide therapeutics, thereby facilitating researchers' access to innovative drugs in critical areas of healthcare.
Operator of a biotechnology company intended to develop medicine to reverse cancer cell immortality. The company's medicine specializes in inhibiting cancer cell immortality by undergoing immortalization process, leaving healthy cells intact, enabling patients to get cured of diseases such as cancer.
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.
DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics aimed at treating patients with rare and chronic diseases globally. The company utilizes innovative technology to enhance the delivery of RNA medicines to various tissues and organ systems, effectively addressing limitations faced by earlier platforms, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's therapies target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017, the company is headquartered in San Diego, California.
AmacaThera Inc. is a biotechnology company based in Toronto, Canada, established in 2016. The company specializes in developing and commercializing an innovative injectable hydrogel platform technology aimed at enhancing medical treatments. This technology is designed to localize and sustain drug delivery, thereby improving patient outcomes across various therapeutic areas. AmacaThera's hydrogel consists of a reversible and fast-gelling physical blend of hyaluronan and methylcellulose, which liquefies under force. This unique formulation assists healthcare providers in reducing post-operative pain for patients, showcasing the potential of AmacaThera's approach in addressing significant medical needs.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.
It was founded in 2010 and is headquartered in Houston, Texas.
Basking Biosciences
Seed Round in 2020
Basking Biosciences is a startup that’s developing a therapy to restore blood flow to the brain during ischemic stroke, preventing hemorrhage and long-term damage.
Phenomic AI is a developer of a drug discovery platform designed to discovery and optimize therapeutics directly against phenotypic assays.The company's platform uses artificial intelligence to analyze phenotypes in complex disease models including high-content co-culture and 3D assays, enabling pharmaceutical companies to discover drugs in an easier way.
Bright Angel Therapeutics is a developer of novel therapeutics designed to provide treatment of drug-resistant and life-threatening fungal infections. The company's services increases efficacy of current treatments and eradicates drug resistance by targeting the stress responses required by fungi for survival, virulence and drug resistance, enabling users to overcome the frequent emergence of clinical resistance largely responsible for the severe morbidity and mortality associated with infection by diverse fungal pathogens.
AmacaThera Inc. is a biotechnology company based in Toronto, Canada, established in 2016. The company specializes in developing and commercializing an innovative injectable hydrogel platform technology aimed at enhancing medical treatments. This technology is designed to localize and sustain drug delivery, thereby improving patient outcomes across various therapeutic areas. AmacaThera's hydrogel consists of a reversible and fast-gelling physical blend of hyaluronan and methylcellulose, which liquefies under force. This unique formulation assists healthcare providers in reducing post-operative pain for patients, showcasing the potential of AmacaThera's approach in addressing significant medical needs.
Forkhead BioTherapeutics Inc develops oral therapy to treat insulin-dependent diabetes. The company offers Foxin, an oral agent which helps in targeted deletion of FOXO1 protein that restores normal insulin production and normalizes glucose metabolism. The company was incorporated in 2017 and is based in New York, New York.
QurAlis Corporation is a biotechnology company focused on discovering and developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurological diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis aims to address the genetic underpinnings of ALS, leveraging its proprietary platforms and biomarkers to create targeted treatments. The company's pipeline includes innovative therapies designed to restore dysfunctional cellular processes, treat overactive neurons, and eliminate toxic proteins associated with the disease. By concentrating on genetically validated targets, QurAlis seeks to advance antisense oligonucleotides and small molecule programs that can effectively manage various subtypes of ALS, ultimately working to halt disease progression and improve patient outcomes. QurAlis operates as a subsidiary of Q-State Biosciences, Inc.
Riparian Pharmaceuticals, Inc. is a biotechnology company based in Boston, Massachusetts, focused on discovering innovative therapeutics that address endothelial dysfunction and enhance vascular health. Established in 2012, the company employs advanced models of vascular pathophysiology to develop medical therapies aimed at treating cardiovascular and inflammatory diseases. By targeting new vasoprotective pathways, Riparian Pharmaceuticals seeks to improve endothelial function and reduce vascular complications associated with both common and rare vascular diseases. This approach is designed to enable healthcare providers to achieve better outcomes for their patients.
Arthrosi Therapeutics
Series A in 2017
Arthrosi Therapeutics is a biotechnology company that focuses on drug discovery and development. The company was founded in 2017 and based in Laguna Hills, California.
Dogma Therapeutics is a biotechnology company based in the United States that specializes in developing small molecule inhibitors targeting PCSK9, a protein involved in cholesterol regulation. The firm has successfully identified orally bioavailable small molecule inhibitors that effectively lower blood lipid levels, addressing a significant challenge in the pharmaceutical industry, where previous attempts primarily relied on monoclonal antibodies. Utilizing high-resolution x-ray structures of their compounds bound to PCSK9, Dogma Therapeutics employs structure-based design to achieve high-affinity interactions. This innovative approach aims to transform the treatment landscape for cholesterol management and improve the economic viability of PCSK9-based therapies.
Flash Therapeutics
Series A in 2016
Flash is developing an oral compound to prevent AML relapse using novel findings linking HCK to AML. This small molecule will inhibit HCK and FLT3-ITD for the treatment of cancer. They have identified five potential compounds for further testing. One is moving on to IND filing while the other four are going to begin animal toxicology testing.
Tabomedex Biosciences, Inc. develops inhibitors of molecules for treatment of type two diabetes. It offers allosteric MK2 inhibitors, which ameliorate insulin sensitivity and have robust cardio protective effects. The company was founded in 2017 and is based in Boxford, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.